Stifel Financial Corp Galmed Pharmaceuticals Ltd. Transaction History

Stifel Financial Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$3.3 - $6.84 $34,102 - $70,684	-10,334 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$3.61 - $6.75 $5,624 - $10,516	-1,558 Reduced 13.1%	10,334 $61,000
Q3 2019 Nov 13, 2019	SELL	$4.62 - $7.11 $17,685 - $27,217	-3,828 Reduced 24.35%	11,892 $52,000
Q2 2019 Aug 14, 2019	BUY	$5.68 - $8.68 $19,323 - $29,529	3,402 Added 27.62%	15,720 $114,000
Q1 2019 May 14, 2019	SELL	$7.27 - $9.07 $31,333 - $39,091	-4,310 Reduced 25.92%	12,318 $102,000

Q4 2018 Feb 13, 2019	SELL	$6.59 - $14.47 $1,673 - $3,675	-254 Reduced 1.5%	16,628 $113,000
Q3 2018 Nov 13, 2018	SELL	$10.55 - $15.28 $27,619 - $40,003	-2,618 Reduced 13.43%	16,882 $229,000
Q2 2018 Aug 14, 2018	BUY	$5.04 - $17.96 $98,280 - $350,220	19,500 New	19,500 $234,000

Ticker GLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,088,400
Market Cap $7.53M
Description
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.